Denali Therapeutics Inc.

NasdaqGS:DNLI Voorraadrapport

Marktkapitalisatie: US$4.2b

Denali Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Denali Therapeutics is Ryan Watts, benoemd in Aug2015, heeft een ambtstermijn van 9.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.88M, bestaande uit 8.5% salaris en 91.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.57% van de aandelen van het bedrijf, ter waarde $ 66.34M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 8.1 jaar.

Belangrijke informatie

Ryan Watts

Algemeen directeur

US$7.9m

Totale compensatie

Percentage CEO-salaris8.5%
Dienstverband CEO9.3yrs
Eigendom CEO1.6%
Management gemiddelde ambtstermijn5.8yrs
Gemiddelde ambtstermijn bestuur8.1yrs

Recente managementupdates

Recent updates

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 20

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Jul 26
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04
Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09
These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Analyse CEO-vergoeding

Hoe is Ryan Watts's beloning veranderd ten opzichte van Denali Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$427m

Jun 30 2024n/an/a

-US$420m

Mar 31 2024n/an/a

-US$137m

Dec 31 2023US$8mUS$670k

-US$145m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$371m

Dec 31 2022US$9mUS$645k

-US$326m

Sep 30 2022n/an/a

-US$303m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$13mUS$610k

-US$291m

Sep 30 2021n/an/a

US$30m

Jun 30 2021n/an/a

US$56m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$9mUS$589k

US$71m

Sep 30 2020n/an/a

-US$228m

Jun 30 2020n/an/a

-US$216m

Mar 31 2020n/an/a

-US$215m

Dec 31 2019US$5mUS$567k

-US$198m

Sep 30 2019n/an/a

-US$66m

Jun 30 2019n/an/a

-US$55m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$6mUS$545k

-US$36m

Sep 30 2018n/an/a

-US$137m

Jun 30 2018n/an/a

-US$123m

Mar 31 2018n/an/a

-US$91m

Dec 31 2017US$1mUS$481k

-US$88m

Compensatie versus markt: De totale vergoeding ($USD 7.88M ) Ryan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.60M ).

Compensatie versus inkomsten: De vergoeding van Ryan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ryan Watts (48 yo)

9.3yrs

Tenure

US$7,879,267

Compensatie

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Ryan Watts
Co-Founder9.3yrsUS$7.88m1.57%
$ 66.3m
Alexander Schuth
Co-Founder9.7yrsUS$4.17m0.41%
$ 17.3m
Marc Tessier-Lavigne
Co-Founder & Independent Directorno dataUS$431.93k1.47%
$ 62.5m
Carole Ho
Chief Medical Officer & Head of Development9.4yrsUS$4.17m0.15%
$ 6.2m
Tyler Nielsen
Senior Vice President of Corporate Financeno datageen gegevensgeen gegevens
Dana Andersen
Chief Technical and Manufacturing Officer6.3yrsgeen gegevensgeen gegevens
Joe Lewcock
Chief Scientific Officer4.3yrsgeen gegevensgeen gegevens
Laura Hansen
Vice President of Investor Relations4.8yrsgeen gegevensgeen gegevens
Chris Walsh
General Counsel5.8yrsgeen gegevensgeen gegevens
Mark Rowen
Vice President of Corporate Development1.8yrsgeen gegevensgeen gegevens
Cindy Dunkle
Chief People Officerno datageen gegevensgeen gegevens
Katie Peng
Chief Commercial Officer3.2yrsgeen gegevensgeen gegevens

5.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DNLI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Ryan Watts
Co-Founder9.7yrsUS$7.88m1.57%
$ 66.3m
Marc Tessier-Lavigne
Co-Founder & Independent Director9.7yrsUS$431.93k1.47%
$ 62.5m
Vicki Sato
Independent Chairperson9.6yrsUS$459.43k0.074%
$ 3.1m
Jay Flatley
Independent Director9.6yrsUS$444.43k0.24%
$ 10.1m
Eric Reiman
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Schenkein
Independent Director9.6yrsUS$439.43k0.051%
$ 2.2m
David Holtzman
Member of Scientific Advisory Board4yrsgeen gegevensgeen gegevens
Peter Klein
Independent Director6.7yrsUS$439.43k0.011%
$ 459.8k
Jennifer Cook
Independent Director6yrsUS$429.43k0.0098%
$ 416.6k
Steve Krognes
Director2.5yrsUS$419.43k0.58%
$ 24.5m
Scott Biller
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Stacie Weninger
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens

8.1yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DNLI wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).